Enzo Biochem Inc
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development pro… Read more
Enzo Biochem Inc (ENZ) - Net Assets
Latest net assets as of April 2025: $43.40 Million USD
Based on the latest financial reports, Enzo Biochem Inc (ENZ) has net assets worth $43.40 Million USD as of April 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.52 Million) and total liabilities ($20.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.40 Million |
| % of Total Assets | 68.33% |
| Annual Growth Rate | 2.19% |
| 5-Year Change | -3.89% |
| 10-Year Change | 31.7% |
| Growth Volatility | 465.2 |
Enzo Biochem Inc - Net Assets Trend (1986–2024)
This chart illustrates how Enzo Biochem Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enzo Biochem Inc (1986–2024)
The table below shows the annual net assets of Enzo Biochem Inc from 1986 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-07-31 | $56.11 Million | -28.49% |
| 2023-07-31 | $78.46 Million | +44.07% |
| 2022-07-31 | $54.46 Million | -20.59% |
| 2021-07-31 | $68.59 Million | +17.48% |
| 2020-07-31 | $58.38 Million | -32.14% |
| 2019-07-31 | $86.03 Million | +6.05% |
| 2018-07-31 | $81.12 Million | -8.72% |
| 2017-07-31 | $88.87 Million | -0.76% |
| 2016-07-31 | $89.55 Million | +110.19% |
| 2015-07-31 | $42.61 Million | +15.31% |
| 2014-07-31 | $36.95 Million | +8.26% |
| 2013-07-31 | $34.13 Million | -30.49% |
| 2012-07-31 | $49.10 Million | -44.65% |
| 2011-07-31 | $88.72 Million | -8.56% |
| 2010-07-31 | $97.02 Million | -16.92% |
| 2009-07-31 | $116.78 Million | -15.55% |
| 2008-07-31 | $138.29 Million | -2.54% |
| 2007-07-31 | $141.89 Million | +48.44% |
| 2006-07-31 | $95.59 Million | -11.71% |
| 2005-07-31 | $108.27 Million | +3.94% |
| 2004-07-31 | $104.17 Million | -4.77% |
| 2003-07-31 | $109.38 Million | +4.44% |
| 2002-07-31 | $104.73 Million | +7.40% |
| 2001-07-31 | $97.52 Million | +11.86% |
| 2000-07-31 | $87.18 Million | +15.31% |
| 1999-07-31 | $75.60 Million | +9.88% |
| 1998-07-31 | $68.80 Million | +7.50% |
| 1997-07-31 | $64.00 Million | +15.73% |
| 1996-07-31 | $55.30 Million | -9.49% |
| 1995-07-31 | $61.10 Million | +19.34% |
| 1994-07-31 | $51.20 Million | +58.51% |
| 1993-07-31 | $32.30 Million | -2.12% |
| 1992-07-31 | $33.00 Million | +2900.00% |
| 1991-07-31 | $1.10 Million | -91.34% |
| 1990-07-31 | $12.70 Million | -15.89% |
| 1989-07-31 | $15.10 Million | -21.76% |
| 1988-07-31 | $19.30 Million | -18.57% |
| 1987-07-31 | $23.70 Million | -3.66% |
| 1986-07-31 | $24.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enzo Biochem Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6791.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $521.00K | 0.93% |
| Other Comprehensive Income | $1.89 Million | 3.36% |
| Other Components | $348.13 Million | 620.43% |
| Total Equity | $56.11 Million | 100.00% |
Enzo Biochem Inc Competitors by Market Cap
The table below lists competitors of Enzo Biochem Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
D3 Energy Ltd
AU:D3E
|
$16.46 Million |
|
Pacific Online Limited
PINK:PCOLF
|
$16.47 Million |
|
Havila Kystruten AS
OL:HKY
|
$16.47 Million |
|
Nexus Minerals Ltd
AU:NXM
|
$16.47 Million |
|
PT TBS Energi Utama Tbk
F:6AU
|
$16.44 Million |
|
Targovax ASA
LSE:0RIS
|
$16.43 Million |
|
MMP Industries Limited
NSE:MMP
|
$16.42 Million |
|
Yjn Co.,Ltd.
TWO:3191
|
$16.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enzo Biochem Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 78,462,000 to 56,112,000, a change of -22,350,000 (-28.5%).
- Net loss of 26,078,000 reduced equity.
- Other comprehensive income increased equity by 7,000.
- Other factors increased equity by 3,721,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.08 Million | -46.47% |
| Other Comprehensive Income | $7.00K | +0.01% |
| Other Changes | $3.72 Million | +6.63% |
| Total Change | $- | -28.49% |
Book Value vs Market Value Analysis
This analysis compares Enzo Biochem Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.36x to 0.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-07-31 | $1.48 | $0.54 | x |
| 1987-07-31 | $1.58 | $0.54 | x |
| 1988-07-31 | $1.31 | $0.54 | x |
| 1989-07-31 | $1.00 | $0.54 | x |
| 1990-07-31 | $0.81 | $0.54 | x |
| 1991-07-31 | $0.07 | $0.54 | x |
| 1992-07-31 | $1.81 | $0.54 | x |
| 1993-07-31 | $1.35 | $0.54 | x |
| 1994-07-31 | $1.75 | $0.54 | x |
| 1995-07-31 | $2.08 | $0.54 | x |
| 1996-07-31 | $1.91 | $0.54 | x |
| 1997-07-31 | $2.17 | $0.54 | x |
| 1998-07-31 | $2.20 | $0.54 | x |
| 1999-07-31 | $2.44 | $0.54 | x |
| 2000-07-31 | $2.66 | $0.54 | x |
| 2001-07-31 | $3.00 | $0.54 | x |
| 2002-07-31 | $3.24 | $0.54 | x |
| 2003-07-31 | $3.24 | $0.54 | x |
| 2004-07-31 | $3.29 | $0.54 | x |
| 2005-07-31 | $3.30 | $0.54 | x |
| 2006-07-31 | $2.97 | $0.54 | x |
| 2007-07-31 | $4.05 | $0.54 | x |
| 2008-07-31 | $3.75 | $0.54 | x |
| 2009-07-31 | $3.11 | $0.54 | x |
| 2010-07-31 | $2.55 | $0.54 | x |
| 2011-07-31 | $2.31 | $0.54 | x |
| 2012-07-31 | $1.27 | $0.54 | x |
| 2013-07-31 | $0.86 | $0.54 | x |
| 2014-07-31 | $0.87 | $0.54 | x |
| 2015-07-31 | $0.94 | $0.54 | x |
| 2016-07-31 | $1.92 | $0.54 | x |
| 2017-07-31 | $1.92 | $0.54 | x |
| 2018-07-31 | $1.73 | $0.54 | x |
| 2019-07-31 | $1.81 | $0.54 | x |
| 2020-07-31 | $1.22 | $0.54 | x |
| 2021-07-31 | $1.42 | $0.54 | x |
| 2022-07-31 | $1.12 | $0.54 | x |
| 2023-07-31 | $1.60 | $0.54 | x |
| 2024-07-31 | $1.10 | $0.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enzo Biochem Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -81.73%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.53x
- Recent ROE (-46.47%) is below the historical average (-38.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 6.10% | 20.55% | 0.10x | 3.06x | $-960.00K |
| 1987 | -6.75% | -18.39% | 0.11x | 3.19x | $-3.97 Million |
| 1988 | -18.13% | -38.46% | 0.13x | 3.62x | $-5.43 Million |
| 1989 | -27.15% | -33.88% | 0.16x | 4.94x | $-5.61 Million |
| 1990 | -32.28% | -21.13% | 0.29x | 5.24x | $-5.37 Million |
| 1991 | -981.82% | -54.55% | 0.40x | 44.82x | $-10.91 Million |
| 1992 | -1.82% | -2.93% | 0.41x | 1.51x | $-3.90 Million |
| 1993 | -21.36% | -34.50% | 0.42x | 1.47x | $-10.13 Million |
| 1994 | 10.35% | 23.25% | 0.35x | 1.27x | $180.00K |
| 1995 | 9.17% | 17.67% | 0.44x | 1.19x | $-510.00K |
| 1996 | -13.92% | -22.32% | 0.55x | 1.14x | $-13.23 Million |
| 1997 | 2.34% | 4.30% | 0.52x | 1.05x | $-4.90 Million |
| 1998 | 4.94% | 8.42% | 0.56x | 1.05x | $-3.48 Million |
| 1999 | 8.60% | 14.67% | 0.56x | 1.04x | $-1.06 Million |
| 2000 | 7.60% | 13.24% | 0.54x | 1.06x | $-2.09 Million |
| 2001 | 6.99% | 11.66% | 0.57x | 1.06x | $-2.94 Million |
| 2002 | 6.61% | 12.82% | 0.49x | 1.04x | $-3.55 Million |
| 2003 | 3.51% | 7.28% | 0.46x | 1.06x | $-7.09 Million |
| 2004 | -5.98% | -14.96% | 0.38x | 1.06x | $-16.65 Million |
| 2005 | 2.77% | 6.92% | 0.37x | 1.08x | $-7.82 Million |
| 2006 | -16.39% | -39.34% | 0.39x | 1.06x | $-25.23 Million |
| 2007 | -9.35% | -25.06% | 0.33x | 1.12x | $-27.45 Million |
| 2008 | -7.70% | -13.69% | 0.50x | 1.12x | $-24.48 Million |
| 2009 | -20.18% | -26.31% | 0.67x | 1.14x | $-35.24 Million |
| 2010 | -22.92% | -22.90% | 0.84x | 1.19x | $-31.93 Million |
| 2011 | -14.61% | -12.70% | 0.93x | 1.23x | $-21.83 Million |
| 2012 | -79.98% | -38.09% | 1.49x | 1.41x | $-44.18 Million |
| 2013 | -53.43% | -19.46% | 1.59x | 1.73x | $-21.65 Million |
| 2014 | -27.00% | -10.40% | 1.49x | 1.74x | $-13.67 Million |
| 2015 | -5.36% | -2.34% | 1.43x | 1.61x | $-6.55 Million |
| 2016 | 50.57% | 44.06% | 0.92x | 1.25x | $36.33 Million |
| 2017 | -2.82% | -2.32% | 1.00x | 1.21x | $-11.39 Million |
| 2018 | -12.72% | -9.86% | 1.03x | 1.25x | $-18.43 Million |
| 2019 | -114.82% | -121.70% | 0.76x | 1.24x | $-107.38 Million |
| 2020 | -58.05% | -44.58% | 0.68x | 1.93x | $-39.73 Million |
| 2021 | 4.99% | 2.91% | 1.04x | 1.66x | $-3.43 Million |
| 2022 | -41.46% | -21.09% | 1.12x | 1.76x | $-28.02 Million |
| 2023 | 25.86% | 65.32% | 0.25x | 1.55x | $12.44 Million |
| 2024 | -46.47% | -81.73% | 0.37x | 1.53x | $-31.69 Million |
Industry Comparison
This section compares Enzo Biochem Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enzo Biochem Inc (ENZ) | $43.40 Million | 6.10% | 0.46x | $16.44 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |